NCT03791034

Recruiting

Cell Free DNA for the Diagnosis and Treatment in Early NSCLC

Samsung Medical Center Source

Compare

Other study identifiers

Sponsor study identifier

2017-08-041-003

Study Type

observational

Estimated enrollment

700

Locations

1 country

Sites

1

Timeline

Study Start

August 28, 2017

Actual (reported)

Primary Completion

December 31, 2021

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

December 31, 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: recruiting
Estimated enrollment: 700 participants
Study completion date: December 31, 2026
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
August 28, 2017
Actual (reported)
First Submitted
December 29, 2018
Actual (reported)
First Posted
January 2, 2019
Actual (reported)
Primary Completion
December 31, 2021
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2026
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: May 11, 2021
Status Verified: May 2021
Last Update Submitted: May 9, 2021

Conditions

Non-small Cell Lung Cancer

Keywords

Non-small cell lung cancerRecurrencecfDNA

Outcome Measures

Primary Outcomes (1)

Recurrence
Recurrence of primary tumor documented by diagnostic imaging with or without biopsy
24 months

Eligibility Criteria

Age18 Years - 90 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

non-small cell lung cancer patients who undergone curative surgery

You may qualify if:

All subjects need to sign the informed consent form

Sponsors & Collaborators

Guardant Health, Inc.
Industrycollaborator
Samsung Medical Center
Otherlead

Study Sites (1)

Samsung Medical Center

Seoul, 06351, South Korea

RECRUITING

Jhingook Kim, MDCONTACT+82-2-3410-3483 jkimsmc@skku.edu

Biospecimen

Retention: SAMPLES WITH DNA

We will collect peripheral blood cell-free tumor DNA serially in non-small cell lung cancer cancer patients.

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell LungRecurrence

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Jhingook Kim, MD
Samsung Medical Center
STUDY CHAIR

Central Study Contacts

Jhingook Kim, MD

CONTACT

+82-2-3410-3483 jkimsmc@skku.edu

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor

Study Record Dates

First Submitted

December 29, 2018

First Posted

January 2, 2019

Study Start

August 28, 2017

Actual (reported)

Primary Completion

December 31, 2021

Estimated (date passed)

NCT03228277

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

Phase 2Completed

NCT03399669

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Phase 2Unknown

NCT04348149

Lindera Obtusiloba for Non-small Cell Lung Cancer

Not ApplicableCompleted

NCT01823068

Vandetanib in Advanced NSCLC With RET Rearrangement

Phase 2Completed

NCT01482182

Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy

Completed

NCT03486119

A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients

Completed

All subjects have Non-small cell lung cancer which suspected on chest CT or confirmed pathologically preoperatively.

Non-small cell lung cancer have to confirmed pathologically after operation

Clinical stage I - IIIA by AJCC 7th staging system

You may not qualify if:

Have been undergone chemotherapy or radiotherapy due to non-small call lung cancer
Have been diagnosed any type of cancer other than cancer of skin, thyroid, uterine cervix with 3 years before enrollment
Recurrent lung cancer
Stage IIIB, IV by AJCC 7th staging system

Contact the study team to confirm eligibility.

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

December 31, 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

May 11, 2021

Record last verified: 2021-05

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT03791034
Data provider: ClinicalTrials.gov
Source updated: 2021-05-11
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:24:45 UTC

Locations

KR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations